BetterLife Pharma Inc. files as a foreign private issuer, and its SEC reports document current-event disclosures furnished on Form 6-K. The filings include news releases, material change reports, management’s discussion and analysis, financial statements, and CEO and CFO certifications.
BetterLife’s filings cover its biopharmaceutical development focus around BETR-001, financial reporting, liquidity and capital actions, governance updates, and public disclosure matters tied to its Canadian reporting framework and U.S. OTC-quoted security.
BetterLife Pharma Inc. (BETRF) is reported to have a significant shareholder group led by RA Capital Healthcare Fund, L.P., which directly holds 55,420,000 common shares of BetterLife. RA Capital Management, L.P., and its managers Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners of these shares under Section 13(d), and each Reporting Person reports beneficial ownership of 9.0% of BetterLife’s common shares, with shared voting and dispositive power over the same 55,420,000 shares.
The reported percentage ownership is based on 170,965,339 common shares outstanding as of September 10, 2026, plus 447,041,840 common shares issued in a public equity offering that closed on September 15, 2026. The Fund has delegated sole voting and investment power to RA Capital and disclaims beneficial ownership for purposes other than Section 13(d).
BetterLife Pharma Inc. (BETRF) submitted a Form 6-K providing notice that materials for its upcoming Annual General Meeting have been filed. The submission includes the Notice of Annual General Meeting and Information Circular dated September 14, 2026, a Form of Proxy and Return Card, and a Notice and Access document.
The report is signed on behalf of BetterLife Pharma Inc. by Chief Financial Officer Moira Ong on September 15, 2026.
BetterLife Pharma Inc. files its annual Form 20‑F, highlighting a pre‑revenue biotech focused on mental health and antiviral drug candidates such as BETR‑001, MM‑001 and MM‑003. The company reported no revenue for the year ended January 31, 2026 and a net loss of $1,512,918, improved from $3,621,884 in 2025.
Cash was only $12,570 with a working capital deficiency of $6,459,206 and total assets of $219,903, against an accumulated deficit of $120,091,493. Management discloses material uncertainty that casts substantial doubt on the company’s ability to continue as a going concern and notes heavy dependence on additional equity or debt financing.
At January 31, 2026, BetterLife had 151,896,675 common shares outstanding, rising to 161,787,025 by May 29, 2026, and trades on the CSE and OTCQB as a penny stock, with associated volatility and liquidity risks. The filing also details past and current legal matters, including a Quebec lease judgment and concluded U.S. litigation, as well as significant outstanding executive compensation and equity incentive overhang.